PubMed Health⌕ Search

Biomedical subjects

W Saris

Publications and source records attributed to W Saris.

8 recordsLinked to original sources

Serum amyloid A: production by human white adipocyte and regulation by obesity and nutrition.

AIMS/HYPOTHESIS: The acute-phase proteins, serum amyloid As (SAA), are precursors of amyloid A, involved in the pathogenesis of AA amyloidosis. This work started with the characterisation of systemic AA amyloidosis concurrent with SAA overexpression in the subcutaneous white adipose tissue (sWAT) of an obese patient with a leptin receptor deficiency. In the present study a series of histopathological, cellular and gene expression studies was performed to assess the importance of SAA in common obesity and its possible production by mature adipocytes. MATERIALS AND METHODS: Gene expression profiling was performed in the sWAT of two extremely obese patients with a leptin receptor deficiency. Levels of the mRNAs of the different SAA isoforms were quantified in sWAT cellular fractions from lean subjects and from obese subjects before and after a very-low-calorie diet. These values were subsequently compared with serum levels of SAA in these individuals. In addition, histopathological analyses of sWAT were performed in lean and obese subjects. RESULTS: In sWAT, the expression of SAA is more than 20-fold higher in mature adipocytes than in the cells of the stroma vascular fraction (p<0.01). Levels of SAA mRNA expression and circulating levels of the protein are sixfold (p<0.001) and 3.5-fold (p<0.01) higher in obese subjects than in lean subjects, respectively. In lean subjects, 5% of adipocytes are immunoreactive for SAA, whereas the corresponding value is greater than 20% in obese subjects. Caloric restriction results in decreases of 45-75% in levels of the transcripts for the SAA isoforms and in circulating levels of the protein. CONCLUSIONS/INTERPRETATION: The results of the present study indicate that SAA is expressed by sWAT, and its production at this site is regulated by nutritional status. If amyloidosis is seen in the context of obesity, it is possible that production of SAA by adipocytes could be a contributory factor.

Adipocytes↗

Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance.

BACKGROUND: In this report we assess pre-treatment determinants of weight loss and maintenance outcome in The Sibutramine Trial of Obesity Reduction and Maintenance (STORM), a 2 y randomized, double-blind, placebo-controlled, European multicenter study examining the effect of sibutramine (Sib) on inducing and maintaining weight loss in obese subjects. MATERIAL: A total of 605 obese patients (BMI: 30-45 kg/m2) of both gender were included from eight European centers and treated for 24 months. The patients were treated for the initial 6 months by Sib (10 mg/day) and a low-fat low-energy, individualized diet (600 kcal/day deficit). The 467 patients who achieved >5% weight loss after 6 months were randomized 3&ratio;1 to Sib (10 mg/day) (Sib/Sib) and placebo (Sib/Pla) for weight maintenance over a further 18 months. MAIN OUTCOME AND ANALYSES: Pre-treatment individual characteristics were assessed as predictors of 6 months weight loss (kg) and 24 months weight maintenance using simple and multivariate correlation and regression analyses. RESULTS: In univariate analyses, the 6 month weight loss (n=505) was positively associated with pre-treatment body weight (r=0.27), height (r=0.18), fat-free mass (r=0.21) (all P<0.001), fat mass (r=0.13, P<0.03), and resting metabolic rate (r=0.13, P<0.003). However, no relation was found with age, gender, smoking status, age at onset of obesity, or number of previous slimming attempts. The same predictors were found for weight change to endpoint in the Sib/Sib group (n=350), while no predictors were identified in the Sib/Pla (n=114). In the multivariate regression analysis only pre-treatment body weight predicted weight loss at 6 months (P<0.001). Weight change (kg) to 24 month was predicted by: 4.34+0.07*body weight (kg)-4*treatment (Sib=1, Pla=0)-0.06*age (y), (r2=8%, P<0.001). CONCLUSION: Only pre-treatment body weight seems to be an important independent predictor of 6 months weight loss and 24 month weight maintenance in this study on diet and Sib. As only 8% of the variation in 24 months weight change could be explained by the predictors, the clinical value of this information is limited.

Adolescent↗

The role of dietary fat in body fatness: evidence from a preliminary meta-analysis of ad libitum low-fat dietary intervention studies.

The role of high-fat diets in weight gain and obesity has been questioned because of inconsistent reports in the literature concerning the efficacy of ad libitum low-fat diets to reduce body weight. We conducted a meta-analysis of weight loss occurring on ad libitum low-fat diets in intervention trials, and analysed the relationship between initial body weight and weight loss. We selected controlled trials lasting more than 2 months comparing ad libitum low-fat diets with a control group consuming their habitual diet or a medium-fat diet ad libitum published from 1966 to 1998. Data were included from 16 trials with a duration of 2-12 months, involving 1728 individuals. No trials on obese subjects fulfilled the inclusion criteria. The weighted difference in weight loss between intervention and control groups was 2.55 kg (95% CI, 1.5-3.5; P < 0.0001). Weight loss was positively and independently related to pre-treatment body weight (r = 0.52, P < 0.05) and to reduction in the percentage of energy as fat (0.37 kg/%, P < 0.005) in unweighted analysis. Extrapolated to a BMI of about 30 kg/m2 and assuming a 10% reduction in dietary fat, the predicted weight loss would be 4.4 kg (95% CI, 2.0 to -6.8 kg). Because weight loss was not the primary aim in 12 of the 16 studies, it is unlikely that voluntary energy restriction contributed to the weight loss. Although there is no evidence that a high intake of simple sugars contributes to passive overconsumption, carbohydrate foods with a low glycaemic index may be more satiating and exert more beneficial effects on insulin resistance and cardiovascular risk factors. Moreover, an increase in protein content up to 25% of total energy may also contribute to reducing total energy intake. In conclusion, a low-fat diet, high in protein and fibre-rich carbohydrates, mainly from different vegetables, fruits and whole grains, is highly satiating for fewer calories than fatty foods. This diet composition provides good sources of vitamins, minerals, trace elements and fibre, and may have the most beneficial effect on blood lipids and blood-pressure levels. A reduction in dietary fat without restriction of total energy intake prevents weight gain in subjects of normal weight and produces a weight loss in overweight subjects, which is highly relevant for public health.

Body Mass Index↗

Is weight cycling detrimental to health? A review of the literature in humans.

Weight cycling has been hypothesized to have deleterious metabolic, behavioral and health consequences. The majority of clinical studies in humans do however not support the hypothesis that weight cycling per se influences the amount of velocity of subsequent weight loss. Both natural and experimental weight cycling studies have failed to demonstrate permanent alterations of body composition or body fat distribution. Studies found little evidence that weight cycling affects resting energy expenditure. Further research on postulated effects of weight cycling on other components of energy expenditure is needed. A history of weight cycling is not related to alterations in fat mobilization or in cardiovascular risk factors such as blood pressure and serum lipids, but weight variability may be associated with decreases in glucose tolerance over time. The potential impact of weight cycling on dietary preference for fat, on psychological adjustment or on disordered eating behavior, including binge eating, deserves further investigation. The data from large epidemiological databases suggesting a link between body weight fluctuation and excess mortality are sufficiently provocative to encourage further research into the association, but do not override the potential benefits of weight loss in obese patients.

Body Composition↗

The effects of weight loss and apolipoprotein E polymorphism on serum lipids, apolipoproteins A-I and B, and lipoprotein(a).

Serum levels of lipoprotein(a) [Lp(a)], an independent risk factor for coronary heart disease, are strongly influenced by genetic factors. To evaluate the effect of weight loss on serum Lp(a), 54 normolipidemic obese women were examined before and after a two-month weight reduction programme. A mean weight loss of 10.1 kg was associated with decreases of serum triglycerides, total cholesterol (TC), LDL-C, HDL-C, apo B and apo A-I (P = 0.0001 for all variables), but not Lp(a). However, initial Lp(a) values were related to Lp(a) responses during dietary intervention (P = 0.0001). In subjects with pre-treatment Lp(a) values above 30 mg/dl, a mean 26.3% decrease was observed with weight loss, while no change was found in subjects with low Lp(a) values at baseline (P = 0.007 for group comparison). Apo E polymorphism contributes to the variation in lipid levels in the general population and in the obese. The relative contributions of the apo E locus to the total variance of TC, LDL-C and Lp(a) at baseline in these obese women were estimated to be 3.3, 1.7 and 3.2%, respectively, which are less than previously reported in healthy adults. Pre-treatment TC was increased in subjects with the apo E 3/4 phenotype compared to those with the common apo E 3/3 phenotype (P = 0.03). Apo E polymorphism did not affect Lp(a) levels at baseline nor the changes in lipoprotein variables, including Lp(a), during weight loss. In conclusion, short-term substantial weight loss in normolipidemic obese women resulted in a lowering of Lp(a) only in individuals with pre-treatment Lp(a) levels above 30 mg/dl.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗

Rationale for upper limits of electrolyte replacement during exercise.

The addition of carbohydrate and sodium to sport drinks has been recommended to enhance fluid intake and absorption and to delay fatigue. Other electrolytes (E) which are lost through sweating are also commonly added. However, too many E may lead to increased serum E and osmolality levels, which may negatively influence thermoregulation, depress sweating, and cause gastrointestinal distress. On the other hand, drinking large amounts of plain water to compensate sweat loss may induce hyponatremia. Therefore, literature describing sweat E losses was examined in order to estimate average whole-body E loss and to determine an upper limit for replacement of E with sport drinks. Mean E loss was determined from 13 studies, with +/- 1 SD resulting in a hypothetical range for E losses. Correction for net absorption resulted in an upper limit fo electrolyte replacement. It is suggested that the E levels in sport rehydration drinks should not exceed the upper limit of the range given.

Electrolytes↗

Procainamide therapy, physical performance and energy expenditure in the Schwartz-Jampel syndrome.

The effects of procainamide administration were assessed in a 5-yr-old boy with Schwartz-Jampel syndrome (chondrodystrophic myotonia). Without procainamide the resting metabolic rate was found to be significantly higher than in an age-matched control group. With a serum level of 3.8 mg l-1 procainamide a reduction of the resting metabolic rate of 22% was observed, and times needed to climb stairs and to re-open eyes after forceful contraction (blepharospasm) were significantly reduced.

Child, Preschool↗